YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Nexra Pharma Co., Ltd., (4565.T) announced progress in out-licensing a GPCR-targeted program and its participation in a Series A financing for NewCo, a new company co-founded with SV Health Investors. Under the agreement, NewCo…
(RTTNews) - Nxera Pharma Co., Ltd. (TSE 4565) announced it has received a US$10 million milestone payment from AbbVie Inc. under their ongoing collaboration focused on neurological diseases. This marks the third milestone achieved since th…
(RTTNews) - Nxera Pharma Co., Ltd. (TSE 4565) announced that its partner Holling Bio-Pharma Corp. has received approval from the Taiwan Food and Drug Administration (TFDA) to market and sell QUVIVIQ 25 mg and 50 mg for the treatment of adu…
Nxera Pharma Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investiga…
Nxera Pharma Council brings together leading global scientific and clinical experts in metabolic diseases to guide development of Nxera’s expanding proprietary pipeline Tokyo, Japan and Cambridge, UK, 20 January 2026 – Nxera Pharma Co. Ltd…
(RTTNews) - Japan's Nxera Pharma Co., Ltd. (SOLTF) announced Monday positive top-line results from a Phase 3 study conducted in South Korea evaluating daridorexant 50 mg in adult and elderly patients with insomnia. The company said it plan…
Nxera Pharma Tokyo, Japan and Cambridge, UK, 13 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational,…
Santhera Pharmaceuticals has entered an exclusive licensing agreement with Nxera Pharma for Agamree (Vamorolone) to treat Duchenne muscular dystrophy (DMD) in Australia, Japan, New Zealand, and South Korea. Agamree is a new drug that opera…
(RTTNews) - Nxera Pharma Co., Ltd. (SOLTF, 4565.T) announced it has reached a second milestone in its multi-target discovery collaboration with AbbVie focused on neurological diseases. This milestone, tied to the identification of validate…
Nxera Pharma Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collabo…
* Nxera Pharma press release [https://seekingalpha.com/pr/20194617-nxera-pharma-operational-highlights-and-consolidated-results-for-the-second-quarter-and-first] (OTCPK:SOLTF [https://seekingalpha.com/symbol/SOLTF]): Q2 Revenue of $101.6M.…
Nxera Pharma Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscape Designed to address emerging ar…
Nxera Pharma Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its…
Sosei Group Corporation Tokyo, Japan and Cambridge, UK, 22 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 12 months ended…
Sosei Group Corporation Tokyo,Japan andCambridge,UK, 5 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces the appointment of Mr. Toshihiro Maeda as Chief Operating Officer (“COO”). Mr. Mae…
Sosei Group Corporation Tokyo, Japan and Cambridge, UK, 21 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), announces its President & CEO, Chris Cargill, will present at the 42nd Annual J.P. Morgan He…
Sosei Group Corporation PIVLAZ™, a new drug for prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH), approved in South Korea PIVLAZ will become commercially available in South Korea in early 2025 Tok…
Sosei Group Corporation Both NBI-1117569 (an M4-preferring agonist) and NBI-1117567 (an M1-preferring agonist) are investigational, oral, muscarinic agonists discovered by Sosei Heptares that may have the potential to treat neurological an…
Sosei Group Corporation GPR35 is a novel target with an established genetic association to IBD UK regulatory approval received to commence first-in-human studies Independent commercial analysis supports a worldwide peak sales opportunity o…
Sosei Group Corporation Tokyo, Japan, Cambridge, UK and New York, USA – 10 November 2023 – Sosei Group Corporation (“Sosei Heptares”; TSE: 4565), the international biopharmaceutical company, and Kallyope, a clinical stage biotechnology com…
Sosei Group Corporation Tokyo, Japan and Cambridge, UK, 10 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the thi…
Sosei Group Corporation Tokyo, Japan and Cambridge, UK, 7November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces its President & CEO, Chris Cargill, and Matt Barnes, Head of UK R&D, will participate…
Sosei Group Corporation PF-06954522 was introduced into Pfizer’s Internal Medicine focused clinical pipeline as part of its Q3 2023 results presentation Tokyo, Japan and Cambridge, UK,06 November 2023 – Sosei Group Corporation (“Sosei Hept…
Sosei Group Corporation Tokyo, Japan and Cambridge, UK, 31 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will receive a US$3.75 million milestone payment under the 2019 multi-target Research Collabor…
Sosei Group Corporation NDA includes robust data from a Phase 3 trial that demonstrated efficacy of daridorexant on improving Total Sleep Time and Latency for Sleep Onset, while maintaining a favorable safety profile Sosei Heptares to rece…
Sosei Group Corporation Tokyo, Japan and Cambridge, UK, 25 October 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Friday, 10 November 2023, at 4 pm JST. The meeting will be held virtually via Zoom webinar…
Sosei Group Corporation Tokyo, Japan, and Cambridge, UK, 18 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR-focused structure-based…
Sosei Group Corporation The collaboration combines Sosei Heptares’ leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform for designing high quality novel chemistry leads on a seco…
Nomination of novel drug target based on insights generated through application of Verily’s Immune Profiler platform and Sosei Heptares’ GPCR-focused structure-based drug design expertise SOUTH SAN FRANCISCO, Calif., October 04, 2023--(BUS…
Sosei Group Corporation Tokyo, Japan and Cambridge, UK, 20 September 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) announces the appointment of four new members to its Scientific Advisory Board (SAB) to advise on the Company’s…
Sosei Group Corporation HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 10 August2023 – Sosei…
Sosei Group Corporation Tokyo, Japan and Cambridge, UK, 4August2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first hal…
Eiko Tomita,Vice President, Global Regulatory Affairs at BristolMyers Squibb, elected to the Company’s Board of Directors Candelle Chong promoted to Executive Vice President and Chief of Staff, previously Senior Vice President, Corporate S…
OXFORD, England, Nov. 8, 2022 /PRNewswire/ -- Global techbio company PrecisionLife, pioneers in precision medicine for chronic diseases, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, an…
Collaboration aims to combine Twist’s proprietary synthetic antibody libraries and sophisticated bioinformatics expertise with Sosei Heptares’ world-leading StaR® (stabilized receptor) platform to generate novel antibody leads to disease-r…
Funding comes through the Covid-19 Therapeutics Accelerator, which was set up by Wellcome, Bill & Melinda Gates Foundation and Mastercard TOKYO and CAMBRIDGE, United Kingdom, Dec. 7, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Compa…